托吡酯可减轻帕金森病MPTP损伤狨猴模型中左旋多巴诱导的异动症。
Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease.
作者信息
Silverdale Monty A, Nicholson S L, Crossman A R, Brotchie J M
机构信息
Department of Neurology, Hope Hospital, Salford, Manchester, United Kingdom.
Manchester Movement Disorder Laboratory, School of Biological Science, University of Manchester, Manchester, United Kingdom.
出版信息
Mov Disord. 2005 Apr;20(4):403-409. doi: 10.1002/mds.20345.
Overactive AMPA receptor-mediated transmission may be involved in the pathogenesis of levodopa-induced dyskinesia. The mechanism of action of the anticonvulsant drug topiramate involves attenuation of AMPA receptor-mediated transmission. In this study, the potential antidyskinetic action of topiramate was examined in the MPTP-lesioned marmoset model of Parkinson's disease and levodopa-induced dyskinesia. Topiramate significantly reduced levodopa-induced dyskinesia, without affecting the antiparkinsonian action of levodopa. Topiramate represents an exciting potential novel therapeutic approach to levodopa-induced dyskinesia in patients with Parkinson's disease.
AMPA受体介导的过度传递可能参与左旋多巴诱发的异动症的发病机制。抗惊厥药物托吡酯的作用机制涉及减弱AMPA受体介导的传递。在本研究中，在MPTP损伤的帕金森病和左旋多巴诱发的异动症的狨猴模型中检测了托吡酯潜在的抗异动症作用。托吡酯显著减少了左旋多巴诱发的异动症，而不影响左旋多巴的抗帕金森病作用。托吡酯代表了一种针对帕金森病患者左旋多巴诱发的异动症的令人兴奋的潜在新治疗方法。
Zotero 插件